AR083512A1 - Forma cristalina de un compuesto 3-fenoximetilpirrolidina - Google Patents
Forma cristalina de un compuesto 3-fenoximetilpirrolidinaInfo
- Publication number
- AR083512A1 AR083512A1 ARP110102429A ARP110102429A AR083512A1 AR 083512 A1 AR083512 A1 AR 083512A1 AR P110102429 A ARP110102429 A AR P110102429A AR P110102429 A ARP110102429 A AR P110102429A AR 083512 A1 AR083512 A1 AR 083512A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenoximethyl
- pirrolidine
- compound
- crystalline form
- crystalline
- Prior art date
Links
- -1 PIRROLIDINE COMPOUND Chemical class 0.000 title 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 4
- LZLQEDMHCMNYFK-FZMZJTMJSA-N (3s)-3-[(1s)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine Chemical compound O([C@@H](C(C)C)[C@@H]1CNCC1)C1=CC=C(Cl)C=C1 LZLQEDMHCMNYFK-FZMZJTMJSA-N 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36277310P | 2010-07-09 | 2010-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083512A1 true AR083512A1 (es) | 2013-03-06 |
Family
ID=44510052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102429A AR083512A1 (es) | 2010-07-09 | 2011-07-07 | Forma cristalina de un compuesto 3-fenoximetilpirrolidina |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8163794B2 (enExample) |
| EP (1) | EP2590941A1 (enExample) |
| JP (2) | JP5823512B2 (enExample) |
| KR (1) | KR20130041916A (enExample) |
| CN (1) | CN103038211B (enExample) |
| AR (1) | AR083512A1 (enExample) |
| AU (1) | AU2011276416B2 (enExample) |
| BR (1) | BR112013000602A2 (enExample) |
| CA (1) | CA2803090A1 (enExample) |
| CL (1) | CL2013000085A1 (enExample) |
| CO (1) | CO6680604A2 (enExample) |
| IL (1) | IL223584A0 (enExample) |
| MX (1) | MX2013000334A (enExample) |
| NZ (1) | NZ605490A (enExample) |
| PH (1) | PH12013500051A1 (enExample) |
| RU (1) | RU2013105479A (enExample) |
| SG (1) | SG186789A1 (enExample) |
| TW (1) | TW201206882A (enExample) |
| WO (1) | WO2012006205A1 (enExample) |
| ZA (1) | ZA201300154B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010273645B2 (en) * | 2009-07-13 | 2014-12-04 | Theravance Biopharma R&D Ip, Llc | 3-phenoxymethylpyrrolidine compounds |
| CN103038211B (zh) * | 2010-07-09 | 2015-04-15 | 施万生物制药研发Ip有限责任公司 | 3-苯氧基甲基吡咯烷化合物的结晶形式 |
| US12369722B2 (en) | 2018-05-23 | 2025-07-29 | L&P Property Management Company | Method of disassembling pocketed spring assembly with dimensionally stabilizing substrate |
| US11013340B2 (en) | 2018-05-23 | 2021-05-25 | L&P Property Management Company | Pocketed spring assembly having dimensionally stabilizing substrate |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020151712A1 (en) | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| EP1184372B1 (en) * | 2000-08-31 | 2006-04-26 | Pfizer Limited | Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) |
| WO2005092835A1 (en) * | 2004-03-05 | 2005-10-06 | Eli Lilly And Company | Pharmaceutical compounds |
| CN101506164A (zh) * | 2006-08-23 | 2009-08-12 | 辉瑞产品公司 | 哌啶衍生物 |
| CA2687721A1 (en) * | 2007-06-08 | 2008-12-18 | Arena Pharmaceuticals, Inc. | Crystalline forms of (r)-1-{2-[4'-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto |
| ES2434250T3 (es) * | 2008-07-24 | 2013-12-16 | Theravance, Inc. | Compuestos de 3-(fenoxifenilmetil)pirrolidina |
| EP2419405A1 (en) * | 2009-04-15 | 2012-02-22 | Theravance, Inc. | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
| AU2010273645B2 (en) * | 2009-07-13 | 2014-12-04 | Theravance Biopharma R&D Ip, Llc | 3-phenoxymethylpyrrolidine compounds |
| CN103038211B (zh) * | 2010-07-09 | 2015-04-15 | 施万生物制药研发Ip有限责任公司 | 3-苯氧基甲基吡咯烷化合物的结晶形式 |
-
2011
- 2011-06-30 CN CN201180033815.4A patent/CN103038211B/zh not_active Expired - Fee Related
- 2011-06-30 WO PCT/US2011/042518 patent/WO2012006205A1/en not_active Ceased
- 2011-06-30 BR BR112013000602A patent/BR112013000602A2/pt not_active IP Right Cessation
- 2011-06-30 MX MX2013000334A patent/MX2013000334A/es active IP Right Grant
- 2011-06-30 PH PH1/2013/500051A patent/PH12013500051A1/en unknown
- 2011-06-30 EP EP11738521.1A patent/EP2590941A1/en not_active Withdrawn
- 2011-06-30 US US13/173,204 patent/US8163794B2/en not_active Expired - Fee Related
- 2011-06-30 KR KR1020137001583A patent/KR20130041916A/ko not_active Withdrawn
- 2011-06-30 NZ NZ605490A patent/NZ605490A/en not_active IP Right Cessation
- 2011-06-30 RU RU2013105479/04A patent/RU2013105479A/ru not_active Application Discontinuation
- 2011-06-30 SG SG2012094348A patent/SG186789A1/en unknown
- 2011-06-30 CA CA2803090A patent/CA2803090A1/en not_active Abandoned
- 2011-06-30 AU AU2011276416A patent/AU2011276416B2/en not_active Ceased
- 2011-06-30 JP JP2013518688A patent/JP5823512B2/ja not_active Expired - Fee Related
- 2011-07-07 AR ARP110102429A patent/AR083512A1/es unknown
- 2011-07-08 TW TW100124302A patent/TW201206882A/zh unknown
-
2012
- 2012-03-20 US US13/424,561 patent/US8383669B2/en not_active Expired - Fee Related
- 2012-12-12 IL IL223584A patent/IL223584A0/en unknown
- 2012-12-19 US US13/720,385 patent/US8791151B2/en not_active Expired - Fee Related
-
2013
- 2013-01-07 ZA ZA2013/00154A patent/ZA201300154B/en unknown
- 2013-01-09 CO CO13003305A patent/CO6680604A2/es not_active Application Discontinuation
- 2013-01-09 CL CL2013000085A patent/CL2013000085A1/es unknown
-
2014
- 2014-06-24 US US14/313,422 patent/US9120746B2/en not_active Expired - Fee Related
-
2015
- 2015-03-26 JP JP2015063809A patent/JP2015120752A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011276416A1 (en) | 2013-02-14 |
| US9120746B2 (en) | 2015-09-01 |
| EP2590941A1 (en) | 2013-05-15 |
| KR20130041916A (ko) | 2013-04-25 |
| IL223584A0 (en) | 2013-03-05 |
| US8791151B2 (en) | 2014-07-29 |
| TW201206882A (en) | 2012-02-16 |
| US20150080450A1 (en) | 2015-03-19 |
| CA2803090A1 (en) | 2012-01-12 |
| AU2011276416B2 (en) | 2015-04-02 |
| CN103038211A (zh) | 2013-04-10 |
| NZ605490A (en) | 2014-10-31 |
| MX2013000334A (es) | 2013-02-26 |
| US8163794B2 (en) | 2012-04-24 |
| US20120010265A1 (en) | 2012-01-12 |
| CN103038211B (zh) | 2015-04-15 |
| CO6680604A2 (es) | 2013-05-31 |
| US8383669B2 (en) | 2013-02-26 |
| ZA201300154B (en) | 2013-09-25 |
| WO2012006205A1 (en) | 2012-01-12 |
| JP5823512B2 (ja) | 2015-11-25 |
| SG186789A1 (en) | 2013-02-28 |
| JP2013532170A (ja) | 2013-08-15 |
| PH12013500051A1 (en) | 2017-10-25 |
| JP2015120752A (ja) | 2015-07-02 |
| RU2013105479A (ru) | 2014-08-20 |
| US20120178790A1 (en) | 2012-07-12 |
| US20140018407A1 (en) | 2014-01-16 |
| CL2013000085A1 (es) | 2013-03-15 |
| BR112013000602A2 (pt) | 2016-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301043I1 (nl) | Osilodrostat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van osilodrostatdiwaterstoffosfaat | |
| MY170935A (en) | Neprilysin inhibitors | |
| PH12014502733A1 (en) | Neprilysin inhibitors | |
| MX343620B (es) | Forma polimorfica de clorhidrato de pridopidina. | |
| UA114726C2 (uk) | 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів | |
| SG191175A1 (en) | Neprilysin inhibitors | |
| MX2012000973A (es) | Compuestos para la reduccion de produccion de beta- amiloide. | |
| IL250439A0 (en) | Use of fingolimod, or a phosphate derivative thereof or a pharmaceutical acceptable salt thereof for the preparation of a drug for the treatment of multiple sclerosis | |
| MY163394A (en) | Substituted aminobutyric derivates as neprilysin inhibitors | |
| MX344238B (es) | Compuestos de tetrazol y métodos para preparar y usar los mismos. | |
| ECSP11011391A (es) | Métodos y productos intermedios para preparar agentes farmacéuticos | |
| MY165087A (en) | Neprilysin inhibitors | |
| MY163216A (en) | Compositions and methods for modulating fxr | |
| CR20130023A (es) | Pirazolo[1,5-a]pirimidinas para tratamiento antiviral | |
| MY149731A (en) | Compounds | |
| MY172924A (en) | Neprilysin inhibitors | |
| MX2013007336A (es) | Compuestos de bi-heteroarilo como inhibidores de vps34. | |
| IN2015DN01023A (enExample) | ||
| WO2012159027A3 (en) | Osw-1 analogs and conjugates, and uses thereof | |
| WO2010039920A3 (en) | Boldine compounds for promoting bone growth | |
| AR090209A1 (es) | Polimorfos de 1-(3-terc-butil-1-p-tolil-1h-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1h-indazol-5-iloxi)bencil)urea y composiciones farmaceuticas que los comprenden | |
| CO6680604A2 (es) | Forma cristalina de un compuesto 3-fenocimetilpirrolidina | |
| WO2010093615A3 (en) | Compounds, their syntheses, compositions, and methods to treat cancer | |
| MX342465B (es) | Metodos para tratar enfermedades hematologicas usando 6-ciclohexil-1-hidroxi-4-metil-2(1h)-piridona. | |
| BRPI1012669A2 (pt) | metodo de preparacao de 3,3,5,5-tetrametliciclohexanona, método de preparção de 1-amino-1,3,3,5,5,-pentametilciclohexano ou um sal farmaceuticamente aceitável do mesmo e composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |